Загрузка...
PARP Inhibition: “Targeted” Therapy for Triple Negative Breast Cancer
In contrast to endocrine-sensitive and HER2-positive breast cancer, novel agents capable of treating advanced triple negative breast cancer (TNBC) are lacking. PARP (Poly-(adenosine diphosphate [ADP]-ribose) polymerase) inhibitors are emerging as one of the most promising ‘targeted’ therapeutics to...
Сохранить в:
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2948607/ https://ncbi.nlm.nih.gov/pubmed/20858840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0939 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|